Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Keppra for Neonatal Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Gestational age ≥ 35 weeks~* Postnatal age ≤ 30 days~* Birth weight ≥ 2000 grams~* Clinical or electrographic seizures of any etiology requiring treatment with an antiepileptic medication (as per the judgment of the clinician caring for the patient)~* Parental consent obtained~Exclusion criteria:~* Infants with renal insufficiency indicated by serum creatinine \> 2.0 (as part of pre-screening, labs obtained as part of routine care will be reviewed. Infants who have not had a creatinine drawn will have one drawn as part of the study after consent is obtained. If the baby requires levetiracetam emergently before the results of the creatinine are back, the dose will still be given and levels will still be drawn as per the protocol.~* Infants who have previously received levetiracetam~* Parents refuse consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: 30 Days
- Healthy Volunteers: f

Study Arms:
- Levetiracetam as first line (Type: None): Babies who receive levetiracetam as a first line drug for seizures
- Phenobarbital as first line (Type: None): Babies who receive phenobarbital as a first line drug for seizures and levetiracetam as a second line drug

Based on this trial design, predict the completion outcome and termination type (if applicable).